Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Alex has bispecific patients keep flu and COVID tests at home because fever workup must still rule out infection. In one case, a patient had recurrent CRS fevers and later tested positive for flu B, with cough and congestion distinguishing the infection from her earlier fever-only CRS.

Related Insights

Alex says baseline CRP, ferritin and IL-6 help interpret later changes when a patient develops fever, but they are not specific to CRS and should not guide treatment. IL-6 rises after tocilizumab because the receptor is blocked, making subsequent values hard to interpret in practice.

A critical logistical challenge for administering Tarlatumab is ensuring patients with fever (a potential sign of CRS) are not left waiting in a standard emergency room. An effective strategy involves creating a dedicated protocol so these patients are seen immediately by staff familiar with the drug's toxicities, preventing dangerous delays.

Subtle, early signs of serious T-cell engager toxicities like CRS and ICANS (e.g., mild confusion, headache) can be easily dismissed by patients. Effective management requires educating patients to report these symptoms immediately, as delaying can lead to severe outcomes, shifting focus to proactive patient behavior modification.

The standard of care for CRS has evolved. Instead of waiting for CRS to escalate, institutions now immediately administer dexamethasone and tocilizumab at the first sign of a fever (grade 1), finding it doesn't harm CAR T-cell expansion and improves safety.

Giving tocilizumab prophylactically before bispecific antibody administration is a key strategy to mitigate Cytokine Release Syndrome. This practice, supported by NCCN guidelines and generally reimbursed, significantly reduces CRS risk, making it safer and more feasible to deliver these therapies in an outpatient setting.

Alex and Jennifer describe a 'pill in pocket' approach: patients keep dexamethasone at home. If they call with fever but stable vital signs, they take one dose, monitor temperature every one to two hours, and call back for recurrent fever. Many avoid admission, though repeat fever triggers evaluation.

Suspected interstitial lung disease on chest imaging can closely resemble infectious conditions like pneumonia. Involving pulmonary specialists early for inpatient evaluation, viral testing, or bronchoscopy prevents physicians from unnecessarily stopping effective trastuzumab deruxtecan therapy for a misdiagnosed toxicity, while ensuring true pulmonary complications receive rapid steroid or antibiotic intervention.

Alex says one-and-done vaccines such as RSV, shingles and pneumonia are best given before a bispecific or at least a year after, when immune response is likely better. Flu and COVID vaccines are still recommended, but she spaces them six to eight weeks before PET to avoid vaccine-related adenopathy.

Granulocyte colony-stimulating factor (G-CSF) should be temporarily withheld in patients experiencing unresolved cytokine release syndrome. G-CSF administration can independently trigger low-grade fevers and acute inflammatory symptoms, obscuring whether the patient's presentation is an escalating immune toxicity, infection, or standard drug side effect.

Clinicians often conflate bispecific cytokine release syndrome with CAR-T CRS, creating undue reluctance in community settings. Bispecific grade 1 CRS typically presents with mild fevers (around 101°F) that rarely escalate into high-grade fevers (103°F–104°F) seen in CAR-T. In most cases, bispecific grade 1 CRS is safely controlled in the outpatient setting with acetaminophen, ibuprofen, or a single dose of oral dexamethasone.

At-home flu and COVID tests clarify CRS vs infection | RiffOn